Next Article in Journal
Protein Prenyltransferases and Their Inhibitors: Structural and Functional Characterization
Next Article in Special Issue
AMPK and the Challenge of Treating Hypoxic Pulmonary Hypertension
Previous Article in Journal
Mechanisms of the FMR1 Repeat Instability: How Does the CGG Sequence Expand?
Previous Article in Special Issue
Structural and Hemodynamic Changes of the Right Ventricle in PH-HFpEF
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 23
Issue 10
10.3390/ijms23105426
Review Report
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Article
Peer-Review Record

Reversal of Right Ventricular Hypertrophy and Dysfunction by Prostacyclin in a Rat Model of Severe Pulmonary Arterial Hypertension

Int. J. Mol. Sci. 2022, 23(10), 5426; https://doi.org/10.3390/ijms23105426
by Rebecca R. Vanderpool 1, Anastasia Gorelova 2,3, Yiran Ma 2,4, Mohammad Alhamaydeh 5, Jeffrey Baust 2, Sruti Shiva 2,3, Stevan P. Tofovic 2,3, Jian Hu 2, Seyed Mehdi Nouraie 2,6, Mark T. Gladwin 2,6, Maryam Sharifi-Sanjani 2,4,*,† and Imad Al Ghouleh 2,3,4,*,†
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Int. J. Mol. Sci. 2022, 23(10), 5426; https://doi.org/10.3390/ijms23105426
Submission received: 16 April 2022 / Revised: 6 May 2022 / Accepted: 9 May 2022 / Published: 12 May 2022
(This article belongs to the Special Issue Advances Research on Pulmonary Hypertension)

Round 1

Reviewer 1 Report

The paper is well written.

This is an important,  unicentric, although with authors from two University Centers in the USA, well designed, an elegant study showing that

reprostinil, a prostacyclin analog that is among the most effective and widely used therapies for pulmonary arterial hypertension (PAH), also benefits the right ventricle (RV) in an experimental model of pre-clinical rat Sugen-chronic hypoxia (SuCH) model of severe PAH that closely resembles the PAH human disease. The methods used are adequate for evaluation of the RV from a functional viewpoint, with assessing pressure-volume loops, and also aimed to identify altered mechanisms within the RV, with RV samples that were used to perform a custom RNA array analysis, histological staining, and further analyzes for protein and transcript levels. On a translational basis, this ideally could help to better understand the patient's symptoms and prognosis when developing RV failure in the reckoning of the PAH. The study is well designed and well-illustrated. The references are appropriate.The Authors have to be commended for their contribution to clarifying prostacyclin analogs use in another context tool for more correct and more comprehensive indications in PAH. I have only a minor suggestion that it would be very much useful to know about future studies that the authors suggest in the field and also, if possible, how the authors see the present results of this experimental study being applied to the clinical area.  Best regards,  

Author Response

Please see the attachment.

Author Response File: Author Response.docx

Reviewer 2 Report

This manuscript entitled "Reversal of Right Ventricular Hypertrophy and Dysfunction by Prostacyclin in a Rat Model of Severe Pulmonary Arterial Hypertension" by Vanderpool et al tries to elucidate the load-independent effect of prostacyclin on the RV in PAH.

This is a well-written excellent report, and I approve of its publication with minor modifications.

1: Please put a full name for IVC in line 140

2: In line 148, the author wrote "no significant change." Please put a p-value.

3: There are several typo/errors.  Please check those carefully. Below are the examples.

Line96: <0.001 <0.001

many figures: ml. should be ul.

Line 409: Check the unit

Author Response

Please see the attachment.

Author Response File: Author Response.docx

Back to TopTop